澳優(1717.HK)直線拉昇漲10% 一季度純利預增72.2%-78.8%
格隆匯4月27日丨午間公佈業績預告的澳優(1717.HK)午後直線拉昇,目前漲幅擴大至9.89%報14港元,暫成交7349萬港元,最新總市值227億港元。盤中最高價14.1港元,創2019年8月以來新高。截至目前,該股年內累漲25%。
澳優公佈,集團2020年1-3月的財務表現將錄得顯著增長。預計一季度實現收入約19.10億元-19.35億元,同比增25.7%-27.4%;公司權益持有人應占利潤約2.61億元-2.71億元,同比增加72.2%-78.8%;及經調整公司權益持有人應占利潤約2.90億元-3.00億元,同比增加49.1%-54.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.